查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827959

避孕藥市場按類型、劑型、作用機制、材料類型、使用期限、使用頻率、銷售管道、應用和最終用戶分類 - 2025-2032 年全球預測

Contraceptive Market by Type, Formulation, Mode Of Action, Material Type, Duration, Usage Frequency, Sales Channel, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年避孕藥具市場將成長 690.2 億美元，複合年成長率為 7.60%。

主要市場統計數據
基準年2024年 384億美元
預計2025年 411.3億美元
預測年份：2032年 690.2億美元
複合年成長率（%） 7.60%

現代避孕領域的策略方向，強調創新、可近性、監管細節和以使用者為中心的優先事項

避孕領域正處於曲折點，臨床創新、不斷變化的消費者期望以及不斷變化的政策環境正在重塑產品開發和獲取途徑。生物醫學技術和製劑科學的進步正在擴大終端用戶的選擇範圍，而數位健康平台和遠端醫療正在改變避孕藥的研發、劑量和取得途徑。同時，圍繞生殖自主權和整體性的社會對話正在影響需求模式以及產品面臨的監管審查。這些動態要求整個價值鏈上的相關人員不僅要考慮功效和安全性，還要考慮使用者體驗、可接受性和獲取的公平性。

從傳統產品系列轉向面向未來的產品組合，需要深入了解臨床差異化和最終用戶細分。醫療系統和支付方優先考慮長期療效和經濟高效的照護途徑，這會影響籌資策略和劑量決策。同時，製造商和創新者必須加快下一代產品的開發，同時應對複雜的供應鏈、法規遵循和永續性的考量。這些因素的結合，既為定向創新創造了重大機遇，也為那些適應緩慢的組織帶來了嚴重的營運風險。因此，本引言建構了分析其餘部分所反映的更廣泛的模式，並為將科學進步與現實世界的可及性和商業性可行性相結合的實用建議奠定了基礎。

技術、分銷、材料和監管實踐方面的重大系統性變化正在重新定義避孕選擇和交付模式

過去十年，在科技、消費行為和醫療保健系統優先事項的共同推動下，多項變革性變革重新定義了避孕領域。長效、可逆的避孕方法在臨床指南和實踐中變得越來越重要，製造商也強調了其耐用性、易於插入和最小副作用。同時，荷爾蒙和非荷爾蒙製劑的進步拓展了治療方法選擇，包括植入、注射、口服系統、經皮吸收貼片和屏障療法，從而實現了更個人化的護理途徑。

數位化和分銷創新正在加速變革，減少處方獲取和依從性支持方面的摩擦。遠端醫療諮詢與電子商務和線上藥局履約結合，正在改變傳統臨床管道和消費者直銷管道之間的平衡。同時，材料科學的進步，例如傳統乳膠產品的替代品，正在為解決過敏問題和提升用戶舒適度創造機會。監管環境正在適應這些創新，但也帶來了臨床終點、上市後監管和跨境分銷的複雜性。這些轉變並非漸進式的；它們正在改變產品的開發、行銷和交付方式，迫使相關人員在日益互聯的生態系統中重新思考臨床參與、病患教育和供應鏈韌性。

評估主要市場的關稅如何重塑整個避孕供應鏈的採購、材料選擇、庫存規劃和獲取動態

2025年主要經濟體實施的關稅措施立即對全球避孕用品及其組成材料的供應鏈產生了波動。從受影響國家和地區採購原料和零件的製造商面臨更高的到岸成本，這促使他們迅速審查籌資策略和供應商多元化。在許多情況下，契約製造和成品製造商開始評估近​​岸外包方案、雙重採購安排和庫存管理方法，以減輕影響，從而影響了醫院、藥房和電商經銷商的前置作業時間和庫存模式。

除了採購之外，關稅相關的成本壓力也影響了產品配方和材料選擇的策略決策。例如，供應鏈敏感性導致在阻隔產品中使用非乳膠替代品，例如腈綸、聚異戊二烯和聚氨酯。監管合規成本和海關延誤也為時間敏感的產品發布和事後緊急避孕藥帶來了阻​​力，因為這些措施需要快速的通路。臨床醫生和衛生系統因採購時間延誤而負擔沉重，付款人和採購團體開始仔細審查其對總成本的影響，包括對患者取得藥品的下游影響。因此，供應鏈透明度、合約彈性和策略採購成為避孕領域公司的核心競爭力。

將產品類型、配方、作用機制、材料和最終用戶概況與可操作的開發和商業策略聯繫起來的細粒度細分洞察

細分市場差異化為確定產品開發和商業策略的優先順序提供了一個實用框架。依類型，事後緊急避孕藥分為子宮內避孕器和避孕藥；荷爾蒙避孕法分為植入式避孕法、注射式避孕法、口服經皮和透皮貼片；非荷爾蒙避孕法分為屏障避孕法；草藥避孕法分為傳統和自然避孕法，例如阿育吠陀和同類療法；永久性避孕方法則包括輸卵管結紮術和輸精管結紮術。這些差異凸顯了不同的臨床途徑：長效和永久性避孕方法往往需要專科護理和醫療保健系統採購，而避孕藥、貼片和屏障避孕法通常需要更廣泛的基層醫療和零售管道。

就劑型而言，貼片、藥丸和環的依從性和可接受性各有不同。作用機制的分類—預防著床、殺精或抑制排卵—直接影響臨床結果和病患教育重點，並影響標籤檢視和安全監測。材料分為乳膠基和非乳膠基，後者又細分為腈綸、聚異戊二烯和聚氨酯，每種材料在成本、質地和致敏性方面各有優劣。

依使用時間長度和使用頻率細分，可區分長期使用和短期使用、按需使用和常規使用，並突顯參與度和依從性的介入途徑。銷售管道區分線下門市（例如醫院藥局和零售藥局）和線上通路（例如電商平台和線上藥局），並突顯購買行為的變化。應用區分一般用途和性交後使用，並突顯緊急程度和配送要求的差異。終端使用者細分可識別女性和男性群體，進一步將女性細分為青少年、成人和停經後群體，從而影響臨床指導、行銷基調和包裝。這些細分視角提供了一致的地圖，用於根據特定的臨床和消費者需求調整產品功能、監管策略和產品發布。

區域戰略要務，解釋監管多樣性、文化規範、製造地和獲取模式如何影響全球市場上避孕藥具的部署

區域動態對產品採用、監管途徑和分銷模式有重大影響。在美洲，都市區先進的臨床應用和農村地區不均衡的可及性相結合，使得醫療系統購買者必須投資高效、長效的藥物，並為更廣大人群提供便捷的零售和線上銷售管道。健康計畫和公共衛生計畫決定了採購的優先順序，而遠端醫療的擴展則持續改變處方的處方箋和配送方式。

歐洲、中東和非洲的監管和文化多樣性要求企業制定細緻的打入市場策略。一些歐洲法規結構強調嚴格的臨床證據和上市後監測，而一些中東和北非國家則優先考慮本地生產獎勵和公共部門分銷。這些因素會影響臨床試驗設計、產品標籤和合作模式的決策。在許多市場中，人們對避孕的文化態度以及當地醫務人員的作用會影響避孕方法的採用模式，尤其是對於非荷爾蒙和草藥替代品。

亞太地區涵蓋頻譜廣泛，既有高度工業化的供應基地，也有傳統醫藥使用率高、消費者偏好獨特的市場。雖然亞太地區的一些製造能力支持全球材料和成品供應鏈，但當地的監管要求和報銷慣例差異很大。在某些地區，傳統草藥形成了平行的需求管道，企業必須理解並尊重這些管道。整體而言，每個地區的策略都必須在集中生產效率與當地監管合規性以及符合當地文化的商業性模式之間取得平衡，以確保藥品的可及性和接受度。

競爭情報和企業策略揭示了創新、供應鏈彈性和數位服務如何重塑避孕藥研發領域的領導地位

競爭動態青睞那些將差異化臨床資產與韌性供應鏈和卓越患者服務相結合的公司。主要企業正在投資下一代荷爾蒙和非荷爾蒙產品，加速長效製劑的開發，並探索針對男性的藥物，以擴大潛在市場。開發商、契約製造和分銷合作夥伴之間的策略聯盟日益普遍，這不僅能夠加快規模擴張，拓寬通路覆蓋範圍，還能降低資本強度。

其他公司則透過材料創新和使用者體驗重塑來實現差異化，最佳化質地、包裝和說明書，以提高接受度和依從性。遠端醫療整合、依從性支援工具以及網路藥局合作等數位化能力正在成為推動客戶獲取和保留的核心競爭優勢。同時，擁有強大監管能力和多元化製造地的公司更有能力吸收政策和關稅帶來的衝擊。對於尋求收購目標或合作以填補產品組合空白的現有企業而言，將臨床新穎性與敏捷商業化模式相結合的新參與企業既是挑戰，也是機會。總體而言，競爭格局正在從純粹以產品為中心的競爭轉向生態系統競爭，其中服務、供應鏈可靠性和監管敏捷性與臨床差異化同等重要。

高階主管應採取哪些戰術性和策略行動來加強採購、加速材料創新、擴大數位覆蓋範圍，並使其產品組合與細分用戶需求保持一致

產業領導者應優先考慮幾項協同行動，以確保短期穩定和長期成長。首先，多元化供應商基礎並制定緊急採購計劃，將減少貿易中斷和關稅波動帶來的風險。其次，加速非乳膠材料的開發和商業化，將解決過敏問題，提升市場吸引力，同時降低單一材料類別集中的風險。第三，拓展數位管道和遠端醫療夥伴關係關係，將利用不斷變化的購買行為，並透過整合支援工具提高依從性。

同時，企業應根據上述特定細分市場自訂產品系列和通訊，將臨床屬性與最終用戶需求（例如青少年教育、成人便利性和停經後安全考量）結合。積極與監管機構和付款方溝通，明確證據要求和報銷途徑，可以促進產品進入市場並減少上市不確定性。最後，將永續性和道德採購納入採購和生產決策，將維護品牌聲譽並滿足相關人員日益成長的期望。這些行動共同構成了領導者在創新、營運韌性和以客戶為中心的商業化之間尋求平衡的可行藍圖。

透過結合相關人員訪談、文獻綜合、供應鏈映射和情境分析的嚴格混合方法研究途徑檢驗了見解

支撐本分析的研究結合了定性和定量方法，以確保研究的穩健性和實際意義。主要研究包括對臨床醫生、採購負責人、監管專家和分銷主管的結構化訪談，以收集關於臨床應用、採購挑戰和管道動態的第一手觀點。二級資訊來源包括同儕審查的臨床文獻、監管備案文件、產品標籤和公開的政策文件，以檢驗臨床和安全相關的聲明。此外，供應鏈分析繪製了物料流和製造足跡，以評估貿易政策變化對產品的影響。

分析方法包括跨細分市場綜合分析（用於將產品屬性與最終用戶需求結合）和情境分析（用於檢驗政策變化和供應鏈中斷的影響）。研究結果與資料來源和專家評審相結合，以最大程度地減少偏差並提高可靠性。調查方法的局限性包括區域層面數據品質參差不齊以及監管指南的不斷演變，需要定期更新以保持有效性。出於倫理方面的考慮，我們在討論傳統和草藥避孕方法時，與臨床專家溝通並尊重文化背景。這些綜合方法為本報告中提出的見解和建議提供了一個合理的框架。

整體結論將不斷發展的技術、監管和供應鏈動態轉化為相關人員的現實策略重點

總而言之，在技術進步、分銷管道演變、材料創新以及影響臨床和消費行為的政策動態的推動下，避孕領域正在經歷意義深遠的變化。有效的策略應將臨床差異化與營運韌性結合，實現供應商多元化，在適當情況下採用非乳膠材料，並整合數位化服務，以滿足使用者的需求。區域差異和層層細分需要量身定做的方法，既要利用全球製造的優勢，也要尊重當地法規和文化背景。

相關人員若能果斷採取行動，產品系列與明確的最終用戶需求保持一致，同時提高供應鏈透明度和監管參與度，將最有可能獲得長期價值。本文提供的見解和建議旨在幫助企業主管、臨床負責人和商業團隊化複雜為機遇，並做出決策，從而改善可及性、提升用戶體驗，並在快速變化的環境中持續創新。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

第5章 市場洞察

  • 安全性問題導致對非荷爾蒙避孕方法的需求增加
  • 男性避孕措施的採用率不斷提高及其對市場動態的影響
  • 數位健康應用程式和穿戴式裝置整合可追蹤避孕藥具的使用情況
  • 擴大遠端醫療服務，改善避孕諮詢服務的可近性
  • 增加對長效可逆避孕藥的投資以滿足患者偏好

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第8章 避孕藥具市場（按類型）

  • 事後緊急避孕藥
    • 子宮內避孕器（IUD）
    • 口服避孕藥
  • 荷爾蒙
    • 植入式避孕器
    • 注射避孕藥
    • 口服避孕藥
    • 經皮避孕藥
  • 非荷爾蒙
    • 屏障法
    • 草藥避孕藥
      • 阿育吠陀
      • 同類療法
    • 自然療法
  • 永恆的
    • 輸卵管結紮
    • 切除術

第9章 避孕藥市場（按劑型）

  • 修補
  • 丸
    • 單相
    • 多態性
  • 戒指

第10章 避孕藥市場（依作用機轉）

  • 預防植入
  • 殺精作用
  • 抑制排卵

第11章 避孕藥市場（依材料類型）

  • 乳膠基底
  • 不含乳膠
    • 腈綸
    • 聚異戊二烯
    • 聚氨酯

第12章 避孕藥具市場（依使用時長）

  • 長期
  • 短期

第13章 避孕藥具市場（依使用頻率）

  • 酌情使用
  • 一直在使用

第14章 避孕藥具市場銷售管道

  • 離線
    • 醫院藥房
    • 藥局
  • 線上
    • 電商平台
    • 網路藥局

第 15 章避孕藥市場（依應用）

  • 一般用途
  • 性交後使用

第16章 避孕藥具市場（依最終用戶）

  • 女士
    • 青春期
    • 成人
    • 停經後
  • 男性

第17章 避孕藥具市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第18章 避孕藥具市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章 各國避孕藥具市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章 競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Abbvie Inc.
    • Bayer AG
    • Cipla Limited
    • Johnson & Johnson Services, Inc.
    • Lupin Limited
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: MRR-4316E4E895C4

The Contraceptive Market is projected to grow by USD 69.02 billion at a CAGR of 7.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 38.40 billion
Estimated Year [2025] USD 41.13 billion
Forecast Year [2032] USD 69.02 billion
CAGR (%) 7.60%

A strategic orientation to the modern contraceptive environment highlighting innovation, access, regulatory nuance, and user-centric priorities

The contraceptive landscape stands at an inflection point where clinical innovation, shifting consumer expectations, and evolving policy environments converge to reshape product development and access. Advances in biomedical technologies and formulation science are expanding the range of options available to end-users, while digital health platforms and telemedicine are changing how contraception is discovered, prescribed, and obtained. At the same time, societal conversations around reproductive autonomy and inclusivity are influencing both demand patterns and the regulatory scrutiny that products face. These dynamics require stakeholders across the value chain to consider not only efficacy and safety, but also user experience, acceptability, and equity of access.

Transitioning from legacy product portfolios to a future-ready mix requires a deep understanding of clinical differentiation and end-user segmentation. Health systems and payers are emphasizing long-term outcomes and cost-effective care pathways, which in turn affects procurement strategies and formulary decisions. Simultaneously, manufacturers and innovators must navigate complex supply chains, regulatory compliance, and sustainability considerations while accelerating next-generation product development. The combination of these forces creates both significant opportunities for targeted innovation and acute operational risks for organizations that are slow to adapt. Accordingly, this introduction frames the broader patterns that inform the remainder of the analysis and sets the stage for practical recommendations that align scientific progress with real-world access and commercial viability.

Key systemic shifts in technology, distribution, materials, and regulatory practice that are redefining contraceptive choice and delivery models

Over the last decade, several transformative shifts have redefined the contraceptive landscape, driven by converging advances in technology, consumer behavior, and health system priorities. Long-acting reversible contraception has become more prominent in clinical guidelines and practice, prompting manufacturers to emphasize durability, ease of insertion, and minimized side effects. Concurrently, progress in hormonal and non-hormonal formulations-spanning implantables, injectables, oral systems, transdermal patches, and barrier methods-has broadened therapeutic choices, enabling more personalized care pathways.

Digital and distribution innovations have accelerated change by lowering friction for prescription access and adherence support. Telehealth consultations combined with e-commerce and online pharmacy fulfillment are altering the balance between traditional clinical settings and consumer-facing channels. At the same time, material science improvements, including alternatives to conventional latex products, are creating opportunities to address allergy concerns and enhance user comfort. Regulatory landscapes have adjusted to accommodate these innovations, yet also introduce complexity around clinical endpoints, post-market surveillance, and cross-border distribution. Taken together, these shifts are not incremental; they change how products are developed, marketed, and delivered, forcing stakeholders to rethink clinical engagement, patient education, and supply chain resilience in an increasingly interconnected ecosystem.

Assessing how tariff measures in major markets have reshaped sourcing, materials choices, inventory planning, and access dynamics across contraceptive supply chains

The introduction of tariff measures by a major economy in 2025 created immediate reverberations across global supply chains for contraceptive products and their constituent materials. Manufacturers sourcing raw materials or components from affected jurisdictions faced higher landed costs, prompting rapid reassessment of procurement strategies and supplier diversification. In many cases, contract manufacturers and finished-goods producers began evaluating nearshoring options, dual-sourcing arrangements, and stockpiling approaches to mitigate disruption, which in turn affected lead times and inventory models for hospitals, pharmacies, and e-commerce distributors.

Beyond procurement, tariff-related cost pressures influenced strategic decisions concerning product formulation and material selection. For example, supply chain sensitivities accelerated interest in non-latex alternatives such as nitrile, polyisoprene, and polyurethane for barrier products, as firms sought materials with more robust multi-region supply bases. Regulatory compliance costs and customs delays also introduced friction for time-sensitive product launches and for emergency contraceptives that require rapid distribution channels. Clinicians and health systems experienced operational strain when procurement timelines shifted, while payers and purchasing groups began scrutinizing total cost implications, including the downstream effects on patient access. The aggregate effect has been to heighten the importance of supply chain transparency, contractual flexibility, and strategic sourcing as core competencies for companies operating in the contraceptive arena.

Granular segmentation insights that connect product types, formulations, modes of action, materials, and end-user profiles to actionable development and commercial strategies

Segment-level differentiation offers a pragmatic framework for prioritizing product development and commercial strategies. By Type, the market encompasses emergency contraceptives divided into intrauterine devices and pills, hormonal methods including implantable, injectable, oral and transdermal options, non-hormonal approaches featuring barrier methods as well as herbal choices split into Ayurvedic and homeopathic traditions and natural methods, and permanent solutions such as tubal ligation and vasectomy. These distinctions reveal divergent clinical pathways: long-acting and permanent options tend to engage specialist care and health-system procurement, whereas pills, patches, and barrier methods often interact with broader primary care and retail channels.

Considering Formulation, patch, pill and ring formats carry different adherence and acceptability profiles; within pills, the distinction between monophasic and multiphasic regimens informs counseling and side-effect management. Mode of Action segmentation-preventing implantation, spermicidal action, and suppression of ovulation-connects directly to clinical outcomes and patient education priorities, shaping labeling and safety monitoring. Material Type splits into latex-based and non-latex offerings, with the latter subdivided into nitrile, polyisoprene, and polyurethane, each presenting trade-offs in cost, tactile properties, and allergenicity.

Duration and Usage Frequency segmentation-long-term versus short-term and on-demand versus regular use-highlight pathways for engagement and adherence interventions, while Sales Channel distinctions between offline outlets such as hospital pharmacies and retail pharmacies and online channels including e-commerce platforms and online pharmacies underscore shifting acquisition behaviors. Application differentiates general use from post-coital use, signaling differing urgency and distribution requirements. End-User segmentation recognizes female and male cohorts, with further granularity for females across adolescent, adult, and post-menopausal groups, which affects clinical guidance, marketing tone, and packaging. Together, these segmentation lenses provide a cohesive map for aligning product features, regulatory strategy, and go-to-market execution to specific clinical and consumer needs.

Regional strategic imperatives describing how regulatory diversity, cultural norms, manufacturing hubs, and access models shape contraceptive deployment across global markets

Regional dynamics exert a substantial influence on product adoption, regulatory pathways, and distribution models. In the Americas, a mix of advanced clinical adoption in urban centers and uneven access across rural communities creates a dual imperative: invest in both high-efficacy long-acting options for health-system purchasers and accessible retail and online offerings for broader populations. Payer systems and public health programs shape procurement priorities, and telemedicine expansion continues to alter how prescriptions are issued and fulfilled.

Across Europe, Middle East & Africa, regulatory heterogeneity and cultural diversity require nuanced market entry strategies. Regulatory frameworks in parts of Europe emphasize rigorous clinical evidence and post-market surveillance, while certain countries in the Middle East and Africa prioritize local manufacturing incentives and public-sector distribution. These conditions influence decisions around clinical trial design, labeling, and partnership models. In many markets, cultural attitudes toward contraception and the role of community health workers affect adoption patterns, especially for non-hormonal and herbal alternatives.

The Asia-Pacific region presents a broad spectrum from highly industrialized supply hubs to markets with strong traditional medicine use and distinct consumer preferences. Manufacturing capacity in parts of Asia-Pacific supports global supply chains for materials and finished goods, yet local regulatory expectations and reimbursement practices vary substantially. Traditional herbal practices in some locales create parallel demand channels that companies must understand and engage with respectfully. Overall, regional strategies must balance centralized manufacturing efficiencies with local regulatory compliance and culturally informed commercial approaches to ensure both access and acceptance.

Competitive intelligence and corporate strategies revealing how innovation, supply chain resilience, and digital services are reshaping leadership in contraceptive development

Competitive dynamics favor organizations that combine differentiated clinical assets with resilient supply chains and compelling patient-facing services. Leading companies are investing in next-generation hormonal and non-hormonal formulations, accelerating work on long-acting modalities, and exploring male-targeted agents to broaden addressable markets. Strategic alliances between developers, contract manufacturers, and distribution partners are increasingly common, enabling faster scale-up and broader channel reach while mitigating capital intensity.

Other firms are differentiating through material innovation and user experience redesign, optimizing tactile properties, packaging, and instructions for use to improve acceptability and adherence. Digital capabilities, including telehealth integrations, adherence support tools, and e-pharmacy partnerships, are becoming core competitive levers that drive customer acquisition and retention. At the same time, companies with strong regulatory affairs capabilities and diverse manufacturing footprints are better positioned to absorb policy and tariff-driven shocks. Emerging entrants that combine clinical novelty with agile commercialization models present both competition and opportunity for incumbents seeking acquisition targets or partnerships to fill portfolio gaps. Overall, the competitive landscape is shifting from purely product-centric competition to ecosystem competition where service, supply chain reliability, and regulatory agility matter as much as clinical differentiation.

Tactical and strategic actions for executives to strengthen sourcing, accelerate material innovation, expand digital reach, and align portfolios with segmented user needs

Industry leaders should prioritize several coordinated actions to secure both short-term stability and long-term growth. First, diversifying the supplier base and developing contingency sourcing plans will reduce exposure to trade disruptions and tariff volatility; investing in dual-sourcing and qualified regional suppliers enhances operational flexibility. Second, accelerating development and commercialization of non-latex materials will address allergy concerns and broaden market appeal, while simultaneously reducing concentration risk tied to single material classes. Third, expanding digital channels and telehealth partnerships will capture shifting acquisition behavior and improve adherence through integrated support tools.

In parallel, companies should tailor product portfolios and messaging to specific segments identified earlier, aligning clinical attributes with end-user needs such as adolescent education, adult convenience, or post-menopausal safety considerations. Engaging proactively with regulators and payers to clarify evidence requirements and reimbursement pathways will smooth market entry and reduce launch uncertainty. Finally, embedding sustainability and ethical sourcing into procurement and manufacturing decisions will protect brand reputation and respond to growing stakeholder expectations. These actions, taken together, form a pragmatic roadmap for leaders seeking to balance innovation with operational resilience and customer-centric commercialization.

A rigorous mixed-methods research approach combining stakeholder interviews, literature synthesis, supply chain mapping, and scenario analysis to validate insights

The research underpinning this analysis combined qualitative and quantitative approaches to ensure robustness and practical relevance. Primary research included structured interviews with clinicians, procurement officers, regulatory specialists, and distribution executives to capture first-hand perspectives on clinical adoption, sourcing challenges, and channel dynamics. Secondary sources comprised peer-reviewed clinical literature, regulatory filings, product labels, and publicly available policy documents to validate clinical and safety-related assertions. In addition, supply chain analyses mapped material flows and manufacturing footprints to assess vulnerability to trade policy shifts.

Analytical methods included cross-segmentation synthesis to align product attributes with end-user needs and scenario analysis to examine the implications of policy changes and supply-chain disruptions. Findings were triangulated across data sources and expert review to minimize bias and enhance credibility. Limitations of the methodology include variability in region-level data quality and the evolving nature of regulatory guidance, which necessitate periodic updates to maintain relevance. Ethical considerations guided the engagement with clinical experts and respect for cultural contexts when discussing traditional and herbal contraceptive practices. Together, these methods produced a defensible framework for the insights and recommendations presented in this report.

Summative conclusions that translate the evolving technological, regulatory, and supply chain dynamics into pragmatic strategic priorities for stakeholders

In closing, the contraceptive landscape is undergoing meaningful transformation driven by technological progress, evolving distribution channels, materials innovation, and policy dynamics that together influence clinical practice and consumer behavior. Effective strategies will combine clinical differentiation with operational resilience-diversifying suppliers, embracing non-latex materials where appropriate, and integrating digital services to meet users where they seek care. Regional nuances and segmentation layers call for tailored approaches that respect local regulatory and cultural contexts while leveraging global manufacturing strengths.

Stakeholders that act decisively to align product portfolios with clearly defined end-user needs, while strengthening supply chain transparency and regulatory engagement, will be best positioned to capture long-term value. The insights and recommendations offered here are designed to help executives, clinical leaders, and commercial teams convert complexity into opportunity, supporting decisions that improve access, enhance user experience, and sustain innovation in a rapidly changing environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing demand for non-hormonal contraceptive methods driven by safety concerns
  • 5.2. Rising adoption of male contraceptive options and implications for market dynamics
  • 5.3. Integration of digital health apps and wearable devices to track contraceptive usage
  • 5.4. Expansion of telehealth services improving access to contraceptive counseling and delivery
  • 5.5. Increased investment in long-acting reversible contraceptives to meet patient preferences

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contraceptive Market, by Type

  • 8.1. Emergency Contraceptives
    • 8.1.1. IUDs
    • 8.1.2. Pills
  • 8.2. Hormonal
    • 8.2.1. Implantable Contraceptives
    • 8.2.2. Injectable Contraceptives
    • 8.2.3. Oral Contraceptives
    • 8.2.4. Transdermal Contraceptives
  • 8.3. Non-Hormonal
    • 8.3.1. Barrier Methods
    • 8.3.2. Herbal Contraceptives
      • 8.3.2.1. Ayurvedic
      • 8.3.2.2. Homeopathic
    • 8.3.3. Natural Methods
  • 8.4. Permanent
    • 8.4.1. Tubal Ligation
    • 8.4.2. Vasectomy

9. Contraceptive Market, by Formulation

  • 9.1. Patch
  • 9.2. Pill
    • 9.2.1. Monophasic
    • 9.2.2. Multiphasic
  • 9.3. Ring

10. Contraceptive Market, by Mode Of Action

  • 10.1. Prevent Implantation
  • 10.2. Spermicidal Action
  • 10.3. Suppress Ovulation

11. Contraceptive Market, by Material Type

  • 11.1. Latex-Based
  • 11.2. Non-Latex
    • 11.2.1. Nitrile
    • 11.2.2. Polyisoprene
    • 11.2.3. Polyurethane

12. Contraceptive Market, by Duration

  • 12.1. Long-Term
  • 12.2. Short-Term

13. Contraceptive Market, by Usage Frequency

  • 13.1. On-Demand
  • 13.2. Regular Use

14. Contraceptive Market, by Sales Channel

  • 14.1. Offline
    • 14.1.1. Hospital Pharmacy
    • 14.1.2. Pharmacy
  • 14.2. Online
    • 14.2.1. E-Commerce Platforms
    • 14.2.2. Online Pharmacy

15. Contraceptive Market, by Application

  • 15.1. General Use
  • 15.2. Post-Coital Use

16. Contraceptive Market, by End-User

  • 16.1. Female
    • 16.1.1. Adolescent
    • 16.1.2. Adult
    • 16.1.3. Post-Menopausal
  • 16.2. Male

17. Contraceptive Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Contraceptive Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Contraceptive Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Abbvie Inc.
    • 20.3.2. Bayer AG
    • 20.3.3. Cipla Limited
    • 20.3.4. Johnson & Johnson Services, Inc.
    • 20.3.5. Lupin Limited
    • 20.3.6. Merck & Co., Inc.
    • 20.3.7. Pfizer Inc.
    • 20.3.8. Sanofi S.A.
    • 20.3.9. Teva Pharmaceutical Industries Ltd.
    • 20.3.10. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 19. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. EUROPE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. AFRICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. ASEAN CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GCC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. EUROPEAN UNION CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BRICS CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. G7 CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. NATO CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 36. GLOBAL CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 37. CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 38. CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CONTRACEPTIVE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACEPTIVE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 329. AMERICAS CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. AMERICAS CONTRACEPTIVE MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. AMERICAS CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 332. AMERICAS CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 333. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 334. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 335. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 336. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 337. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 338. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 339. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2024 (USD MILLION)
  • TABLE 340. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2025-2032 (USD MILLION)
  • TABLE 341. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 342. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 343. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2024 (USD MILLION)
  • TABLE 344. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PILL, 2025-2032 (USD MILLION)
  • TABLE 345. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 346. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 347. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)

TABLE 3